News

BOSTON -- Investigational crinecerfont reduced the need for glucocorticoids in adults and kids with congenital adrenal hyperplasia (CAH), two phase III trials found. In the adult trial of 182 ...
Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...
Learn about a new drug for classic congenital adrenal hyperplasia (CAH). A top expert explains crinecerfont and its benefits, how it works, and its impact on CAH treatment.
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders caused by defects in adrenal steroid biosynthesis. The most common form, accounting for 90% of CAH cases, is caused ...
Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...
Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and ...
Cite this: ‘Game Changer’ Approved for Congenital Adrenal Hyperplasia - Medscape - December 17, 2024. Comments Commenting is limited to medical professionals.
SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control ...
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia ...
The FDA approved crinecerfont (Crenessity) as a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), the agency announced late Friday. Crinecerfont was approved for use in ...
--Neurocrine Biosciences, Inc. today announced publication of a classic congenital adrenal hyperplasia- focused supplement in The Journal of Clinical Endocrinology& Metabolism, sponsored by the ...
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The ...